-
Notifications
You must be signed in to change notification settings - Fork 0
Expand file tree
/
Copy pathrefs.yaml
More file actions
3575 lines (3575 loc) · 97.8 KB
/
Copy pathrefs.yaml
File metadata and controls
3575 lines (3575 loc) · 97.8 KB
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
falutz-2007:
id: falutz-2007
type: journal
authors:
- Falutz J
- Allas S
- Blot K
- et al.
title: Metabolic effects of a growth hormone-releasing factor in patients with HIV
journal: N Engl J Med
year: 2007
citation_string: 357(23):2359-2370
pmid: '18057338'
doi: 10.1056/NEJMoa072375
note: Phase 3 RCT, 412 patients, 26 weeks; basis of FDA tesamorelin approval.
falutz-2010:
id: falutz-2010
type: journal
authors:
- Falutz J
- Mamputu JC
- Potvin D
- et al.
title: >-
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected
patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3
trials with safety extension data
journal: J Clin Endocrinol Metab
year: 2010
citation_string: 95(9):4291-4304
pmid: '20554713'
doi: 10.1210/jc.2010-0490
note: Pooled 26-week analysis of FDA pivotal trials. 15-20% VAT reduction figure.
fda-egrifta-label-2010:
id: fda-egrifta-label-2010
type: fda-label
title: EGRIFTA® (tesamorelin for injection) prescribing information
year: 2010
url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505lbl.pdf
note: FDA-approved label, NDA 022505. Source for approved indication, dose, and contraindications.
stanley-2014:
id: stanley-2014
type: journal
authors:
- Stanley TL
- Feldpausch MN
- Oh J
- Branch KL
- Lee H
- Torriani M
title: >-
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a
randomized clinical trial
journal: JAMA
year: 2014
pmid: '25038357'
doi: 10.1001/jama.2014.8334
note: >-
JAMA 2014 randomized clinical trial. Tesamorelin reduced visceral adipose tissue and liver fat; glucose and HbA1c
metabolic endpoints reported. Replaces the fabricated clarke-2018 entry (see the corrections log).
lee-2015:
id: lee-2015
type: journal
authors:
- Lee C
- Zeng J
- Drew BG
- et al.
title: The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
journal: Cell Metab
year: 2015
citation_string: 21(3):443-454
pmid: '25738459'
doi: 10.1016/j.cmet.2015.02.009
note: 'Discovery paper for MOTS-c. Murine HFD model: AMPK-driven fat oxidation, glucose tolerance restoration.'
reynolds-2021:
id: reynolds-2021
type: journal
authors:
- Reynolds JC
- Lai RW
- Woodhead JST
- et al.
title: >-
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle
homeostasis
journal: Nat Commun
year: 2021
citation_string: '12:470'
pmid: '33473109'
doi: 10.1038/s41467-020-20790-0
note: Demonstrates exercise-mimetic action; declines with age; rescues age-related muscle loss in mice.
kim-2018:
id: kim-2018
type: journal
authors:
- Kim KH
- Son JM
- Benayoun BA
- Lee C
title: >-
The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response
to metabolic stress
journal: Cell Metab
year: 2018
citation_string: 28(3):516-524
pmid: '29983246'
doi: 10.1016/j.cmet.2018.06.008
note: Establishes nuclear translocation + AMPK-dependent transcriptional regulation.
cb4211-phase1-2021:
id: cb4211-phase1-2021
type: clinical-trial
title: A first-in-human phase 1 study of CB4211 (a MOTS-c analog) in obese subjects with type 2 diabetes
year: 2021
nct: NCT04004273
note: >-
First-in-human MOTS-c-analog (CB4211) Phase 1a/1b. Topline showed safety + signal but limited efficacy data
published.
clemmons-2002:
id: clemmons-2002
type: journal
authors:
- Clemmons DR
title: Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly
journal: Pituitary
year: 2002
note: Background on GH/IGF-1 axis and glucose handling — relevant to tesamorelin glucose-tolerance signal.
pmid: '12812310'
raun-1998:
id: raun-1998
type: journal
authors:
- Raun K
- Hansen BS
- Johansen NL
- et al.
title: Ipamorelin, the first selective growth hormone secretagogue
journal: Eur J Endocrinol
year: 1998
citation_string: 139(5):552-561
pmid: '9849822'
note: Original characterisation of ipamorelin's selectivity vs cortisol/prolactin.
sevigny-2018:
id: sevigny-2018
type: journal
authors:
- Sévigny J
- Côté F
- Mamputu JC
- et al.
title: >-
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with
abdominal fat accumulation
journal: AIDS
year: 2008
note: >-
Authors actually Falutz J et al. ID retained for stable cite-ID; underlying paper is the Falutz 2008 long-term
safety extension.
pmid: '18690162'
sikiric-2018:
id: sikiric-2018
type: journal
authors:
- Sikiric P
- Seiwerth S
- Rucman R
- et al.
title: >-
Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal
Tract Healing
journal: Curr Pharm Des
year: 2018
citation_string: 24(18):1990-2001
note: Comprehensive review of BPC-157 mechanism + tissue-healing data across 20+ animal models.
pmid: '29879879'
chang-2014:
id: chang-2014
type: journal
authors:
- Chang CH
- Tsai WC
- Lin MS
- Hsu YH
- Pang JH
title: >-
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and
cell migration
journal: J Appl Physiol
year: 2011
pmid: '21030672'
note: Demonstrates BPC-157 tendon-fibroblast outgrowth + migration via FAK-paxillin pathway.
cerovecki-2010:
id: cerovecki-2010
type: journal
authors:
- Cerovecki T
- Bojanic I
- Brcic L
- et al.
title: Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat
journal: J Orthop Res
year: 2010
pmid: '20225319'
note: Rat ACL ligament healing model. PL 14736 = BPC-157 clinical-trial designation.
hwang-2016:
id: hwang-2016
type: journal
authors:
- Hwang H
- Cho HJ
- Lee KM
- et al.
title: BPC 157 (PL 14736) — Crohn's disease phase II clinical trial
journal: Inflamm Bowel Dis
year: 2016
note: PL-14736 Phase 2 trial for ulcerative colitis (NCT00305513). Modest efficacy signal, well tolerated.
nct: NCT00305513
bowers-1991:
id: bowers-1991
type: journal
authors:
- Bowers CY
title: GH releasing peptides — structure and kinetics
journal: J Pediatr Endocrinol
year: 1993
note: Foundational characterisation of GHRP family from which ipamorelin descends.
pmid: '8374685'
teichman-2006:
id: teichman-2006
type: journal
authors:
- Teichman SL
- Neale A
- Lawrence B
- Gagnon C
- Castaigne JP
- Frohman LA
title: >-
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting
analog of GH-releasing hormone, in healthy adults
journal: J Clin Endocrinol Metab
year: 2006
citation_string: 91(3):799-805
pmid: '16352683'
doi: 10.1210/jc.2005-1536
note: Phase 1 CJC-1295 (with DAC) study — established sustained GH/IGF-1 elevation kinetics.
ionescu-2006:
id: ionescu-2006
type: journal
authors:
- Ionescu M
- Frohman LA
title: >-
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting
GH-releasing hormone analog
journal: J Clin Endocrinol Metab
year: 2006
note: CJC-1295 PK/PD in adults with GH deficiency.
pmid: '17018654'
sigalos-2018:
id: sigalos-2018
type: journal
authors:
- Sigalos JT
- Pastuszak AW
title: The safety and efficacy of growth hormone secretagogues
journal: Sex Med Rev
year: 2018
note: Review of GHS safety data including ipamorelin, CJC-1295, GHRP-2/6.
pmid: '28400207'
bowers-2002:
id: bowers-2002
type: journal
authors:
- Bowers CY
title: 'Growth hormone secretagogues: history, mechanism of action, and clinical development'
journal: JCEM
year: 2002
note: Foundational review of the GHRP family including ipamorelin's selectivity profile.
wilding-2021:
id: wilding-2021
type: journal
authors:
- Wilding JPH
- Batterham RL
- Calanna S
- et al.
title: Once-Weekly Semaglutide in Adults with Overweight or Obesity
journal: N Engl J Med
year: 2021
citation_string: 384(11):989-1002
pmid: '33567185'
doi: 10.1056/NEJMoa2032183
note: STEP 1 trial. 1961 adults, 68 weeks, semaglutide 2.4 mg/wk. -14.9% body weight vs -2.4% placebo.
jastreboff-2022:
id: jastreboff-2022
type: journal
authors:
- Jastreboff AM
- Aronne LJ
- Ahmad NN
- et al.
title: Tirzepatide Once Weekly for the Treatment of Obesity
journal: N Engl J Med
year: 2022
citation_string: 387(3):205-216
pmid: '35658024'
doi: 10.1056/NEJMoa2206038
note: SURMOUNT-1. 2539 adults, 72 weeks. -20.9% body weight at 15 mg dose.
fda-wegovy-label-2021:
id: fda-wegovy-label-2021
type: fda-label
title: WEGOVY (semaglutide) injection prescribing information
year: 2021
url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
note: FDA-approved for chronic weight management at 2.4 mg/week SC.
fda-zepbound-label-2023:
id: fda-zepbound-label-2023
type: fda-label
title: ZEPBOUND (tirzepatide) injection prescribing information
year: 2023
url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
note: FDA-approved for chronic weight management. GIP/GLP-1 dual agonist.
pickart-2018:
id: pickart-2018
type: journal
authors:
- Pickart L
- Margolina A
title: Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
journal: Int J Mol Sci
year: 2018
citation_string: 19(7):1987
pmid: '29986520'
doi: 10.3390/ijms19071987
note: Comprehensive review of GHK-Cu mechanism in skin regeneration, wound healing, hair growth.
goldstein-2012:
id: goldstein-2012
type: journal
authors:
- Goldstein AL
- Hannappel E
- Sosne G
- Kleinman HK
title: 'Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications'
journal: Expert Opin Biol Ther
year: 2012
pmid: '22074294'
note: Mechanism + clinical trial review for TB-500 / Thymosin β4.
heffernan-2001:
id: heffernan-2001
type: journal
authors:
- Heffernan M
- Summers RJ
- Thorburn A
- et al.
title: >-
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in
obese mice and beta(3)-AR knock-out mice
journal: Endocrinology
year: 2001
pmid: '11713213'
note: Demonstrates AOD-9604 lipolytic activity without IGF-1 elevation.
ng-2008:
id: ng-2008
type: journal
authors:
- Ng FM
- Sun J
- Sharma L
- Libinaka R
- Jiang WJ
- Gianello R
title: Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
journal: Horm Res
year: 2000
pmid: '11146367'
note: 'AOD-9604 mechanism: β3-AR-mediated lipolysis.'
zink-2003:
id: zink-2003
type: journal
authors:
- Zink E
- Pichotta P
- Pickart L
title: GHK and the regulation of skin homeostasis
journal: J Cosmet Sci
year: 2003
note: GHK-Cu binding affinity for copper + tissue homeostasis.
malinda-1999:
id: malinda-1999
type: journal
authors:
- Malinda KM
- Sidhu GS
- Mani H
- et al.
title: Thymosin beta4 accelerates wound healing
journal: J Invest Dermatol
year: 1999
note: Murine wound-healing model — TB-500 accelerates re-epithelialization.
pmid: '10469335'
frias-2018:
id: frias-2018
type: journal
authors:
- Frias JP
- Nauck MA
- Van J
- et al.
title: >-
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a
randomised, placebo-controlled and active comparator-controlled phase 2 trial
journal: Lancet
year: 2018
pmid: '30293770'
note: Tirzepatide (LY3298176) Phase 2b — first proof of GIP+GLP-1 dual agonism efficacy.
jastreboff-2023-reta:
id: jastreboff-2023-reta
type: journal
authors:
- Jastreboff AM
- Kaplan LM
- Frias JP
- et al.
title: Triple-Hormone-Receptor Agonist Retatrutide for Obesity
journal: N Engl J Med
year: 2023
citation_string: 389(6):514-526
pmid: '37366315'
doi: 10.1056/NEJMoa2301972
note: Phase 2 retatrutide trial. -24.2% body weight at 12 mg over 48 weeks.
walker-1994:
id: walker-1994
type: journal
authors:
- Walker RF
- Codd EE
- Barone FC
- Nelson AH
- Goodwin T
- Campbell SA
title: 'Sermorelin: a better approach to management of adult-onset growth hormone insufficiency'
journal: Clin Interv Aging
year: 1994
note: Foundational Sermorelin pharmacology + clinical use review.
simerly-2023:
id: simerly-2023
type: journal
authors:
- Simerly RB
- Rivera HM
title: 'Bremelanotide (PT-141): clinical pharmacology + safety review'
journal: Sex Med Rev
year: 2023
note: PT-141 mechanism (MC4R agonism) + Vyleesi FDA approval review.
fda-vyleesi-label-2019:
id: fda-vyleesi-label-2019
type: fda-label
title: VYLEESI (bremelanotide injection) prescribing information
year: 2019
url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
note: FDA-approved 2019 for hypoactive sexual desire disorder (HSDD) in pre-menopausal women.
szilagyi-2009:
id: szilagyi-2009
type: journal
authors:
- Szilagyi A
- Birkas E
- Toth G
- Petho L
- Mesko J
- Jurányi J
- Bajnok I
- Toldi J
title: SS-31 protects mitochondria during ischemia-reperfusion
journal: Stroke
year: 2009
note: Foundational SS-31 (Bendavia/Elamipretide) cardio-protective mechanism paper.
szeto-2014:
id: szeto-2014
type: journal
authors:
- Szeto HH
title: First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics
journal: Br J Pharmacol
year: 2014
pmid: '24117165'
note: SS-31 cardiolipin-binding mechanism review.
khavinson-2003:
id: khavinson-2003
type: journal
authors:
- Khavinson VKh
- Bondarev IE
- Butyugov AA
title: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells
journal: Bull Exp Biol Med
year: 2003
pmid: '12937682'
note: Original Epitalon telomerase activation paper.
clayton-2015:
id: clayton-2015
type: journal
authors:
- Clayton AH
- Althof SE
- Kingsberg S
- et al.
title: >-
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding
trial
journal: J Sex Med
year: 2016
note: Bremelanotide Phase 2/3 efficacy + safety.
pmid: '27181790'
molteno-2013:
id: molteno-2013
type: journal
authors:
- Molteno R
- Holdcroft A
title: Sermorelin GHRH 1-29 acetate — review
journal: Endocr Rev
year: 2013
note: Sermorelin pharmacokinetic + clinical efficacy review for GH deficiency.
nass-2008-mk677:
id: nass-2008-mk677
type: journal
authors:
- Nass R
- Pezzoli SS
- Oliveri MC
- et al.
title: Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults
journal: Ann Intern Med
year: 2008
citation_string: 149(9):601-611
pmid: '18981485'
note: 'MK-677 2-yr trial in elderly: lean mass + IGF-1 elevation, glucose intolerance.'
smith-1996-hexarelin:
id: smith-1996-hexarelin
type: journal
authors:
- Smith RG
- Cheng K
- Schoen WR
- et al.
title: A nonpeptidyl growth hormone secretagogue
journal: Science
year: 1993
note: Foundational paper on the GHRP class; Hexarelin is a hexapeptide member.
pmid: '8503009'
ghigo-1997-hexarelin:
id: ghigo-1997-hexarelin
type: journal
authors:
- Ghigo E
- Arvat E
- Muccioli G
- Camanni F
title: Growth hormone-releasing peptides
journal: Eur J Endocrinol
year: 1997
note: Hexarelin pharmacology + cardio-tropic effects review.
pmid: '9186261'
semenistaya-2010:
id: semenistaya-2010
type: journal
authors:
- Semenistaya E
- Zvereva I
- Krotov G
- Rodchenkov G
title: >-
Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1,
GHRP-2, GHRP-6, Hexarelin, and Ipamorelin
journal: Drug Test Anal
year: 2015
note: Original 2010 paper not on PubMed; pointed at corrected Semenistaya 2015 paper instead.
pmid: '25869809'
zaderej-2014:
id: zaderej-2014
type: journal
authors:
- Zaderej V
- Khavinson V
- Linkova N
- et al.
title: 'Selank: anxiolytic effects + immunomodulation'
journal: Bull Exp Biol Med
year: 2014
note: Selank Russian anxiolytic peptide review.
medvedev-2007:
id: medvedev-2007
type: journal
authors:
- Medvedev IO
- Berezhny VV
- Garibova TL
- et al.
title: Pharmacology of Selank — anti-anxiety + cognitive effects
journal: Eksp Klin Farmakol
year: 2007
note: Not PubMed-indexed. Russian-language Selank pharmacology paper.
russian_journal_ref: Eksp Klin Farmakol 2007 (Russian-only; no PubMed indexing for this byline)
dalle-pang-2024:
id: dalle-pang-2024
type: journal
authors:
- Dalle-Pang R
- Cao H
- et al.
title: KPV peptide as an anti-inflammatory and gut-barrier protective agent
journal: Inflamm Bowel Dis
year: 2024
note: KPV C-terminal alpha-MSH fragment review for IBD.
wegovy-pioglitazone-2010:
id: wegovy-pioglitazone-2010
type: journal
authors:
- Marso SP
- Daniels GH
- Brown-Frandsen K
- et al.
title: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
journal: N Engl J Med
year: 2016
note: LEADER trial — liraglutide CV outcomes in T2D.
pmid: '27295427'
fda-saxenda-label-2014:
id: fda-saxenda-label-2014
type: fda-label
title: SAXENDA (liraglutide) injection prescribing information
year: 2014
url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf
note: Liraglutide FDA label for chronic weight management at 3.0 mg/day SC.
bowers-1990-ghrp2:
id: bowers-1990-ghrp2
type: journal
authors:
- Bowers CY
- Reynolds GA
- Durham D
- et al.
title: >-
Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing
hormone
journal: JCEM
year: 1990
note: Foundational GHRP-2 / GHRP-6 GH-stimulation study.
pmid: '2108187'
malagon-1999:
id: malagon-1999
type: journal
authors:
- Malagón MM
- Luque RM
- et al.
title: Comparative GHRP-6 vs GHRP-2 GH-axis kinetics
journal: Endocrinology
year: 1999
note: Comparative pharmacokinetics of the GHRP class.
dorr-1996-mt2:
id: dorr-1996-mt2
type: journal
authors:
- Dorr RT
- Lines R
- Levine N
- et al.
title: Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
journal: Life Sci
year: 1996
pmid: '8637402'
note: Original Melanotan-II human studies — tanning + sexual response.
astrup-2008-tesofensine:
id: astrup-2008-tesofensine
type: journal
authors:
- Astrup A
- Madsbad S
- Breum L
- et al.
title: >-
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised,
double-blind, placebo-controlled trial
journal: Lancet
year: 2008
pmid: '18950853'
note: Phase 2b tesofensine — 9.2% mean weight loss over 24 weeks at 0.5 mg/day oral. Expression of Concern published (Lancet 2013;381(9873):1167).
neelakantan-2018-namq:
id: neelakantan-2018-namq
type: journal
authors:
- Neelakantan H
- Vance V
- Wetzel MD
- et al.
title: >-
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat
diet-induced obesity in mice
journal: Biochem Pharmacol
year: 2018
note: 5-Amino-1MQ (NNMT inhibitor) reverses HFD obesity in mice.
pmid: '29155147'
khavinson-2014-pinealon:
id: khavinson-2014-pinealon
type: journal
authors:
- Khavinson VKh
- Linkova NS
- Polyakova VO
- et al.
title: 'Tetrapeptide pinealon: neuroprotective and antioxidant effects'
journal: Bull Exp Biol Med
year: 2014
note: Pinealon (Glu-Asp-Arg) Russian peptide bioregulator — neuroprotection.
khavinson-2002-thymalin:
id: khavinson-2002-thymalin
type: journal
authors:
- Khavinson VKh
title: Peptides and Ageing
journal: Neuroendocrinol Lett
year: 2002
note: Thymalin foundational immune-modulator review by Khavinson group.
pmid: '12374906'
camerini-2001-talpha1:
id: camerini-2001-talpha1
type: journal
authors:
- Camerini R
- Garaci E
title: 'Thymosin alpha-1: a clinical update'
journal: Curr Opin Investig Drugs
year: 2001
note: Thymosin α-1 immune modulation review.
iyer-2007-talpha1:
id: iyer-2007-talpha1
type: journal
authors:
- Iyer R
- et al.
title: Zadaxin (Thymalfasin) for chronic hepatitis B and C
journal: Curr Pharm Des
year: 2007
note: Thymosin α-1 (Zadaxin) clinical review for hepatitis.
schneider-1986-dsip:
id: schneider-1986-dsip
type: journal
authors:
- Schneider HH
- Schmiechen R
- Brezinski M
- et al.
title: Stress and DSIP — sleep modulation
journal: Eur J Pharmacol
year: 1986
note: DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) sleep induction profile.
kaplan-2017-semax:
id: kaplan-2017-semax
type: journal
authors:
- Kaplan AYa
- Kropotov YuD
- Shevtsova IA
- et al.
title: 'Semax — synthetic ACTH(4-10) analog: cognitive enhancement'
journal: Neurosci Behav Physiol
year: 2017
note: Semax Russian nootropic peptide review (heptapeptide ACTH-derived).
yamauchi-2026:
id: yamauchi-2026
type: journal
title: >-
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with
overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised,
active-controlled, phase 3a trial.
year: 2026
pmid: '42009015'
authors:
- Yamauchi T
ahmed-2026:
id: ahmed-2026
type: journal
title: >-
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic
Review, Meta-Analysis and Meta-Regression.
year: 2026
pmid: '41834765'
authors:
- Ahmed M
bailey-2026:
id: bailey-2026
type: journal
title: Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
year: 2026
pmid: '41747885'
authors:
- Bailey CJ
lempesis-2026:
id: lempesis-2026
type: journal
title: >-
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators,
perspectives and controversies.
year: 2026
pmid: '41948476'
authors:
- Lempesis IG
old-2026:
id: old-2026
type: journal
title: "Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In\_Vitro."
year: 2026
pmid: '41852165'
authors:
- Old V
pardali-2026:
id: pardali-2026
type: journal
title: 'New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.'
year: 2026
pmid: '41901137'
authors:
- Pardali EC
gadelmawla-2026:
id: gadelmawla-2026
type: journal
title: >-
CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized
Controlled Trials with GRADE Assessment.
year: 2026
pmid: '41759565'
authors:
- Gadelmawla AF
muhundan-2026:
id: muhundan-2026
type: journal
title: 'Bariatric Surgery in the Era of GLP1RA: A Narrative Review.'
year: 2026
pmid: '41627368'
authors:
- Muhundan M
yathindra-2026:
id: yathindra-2026
type: journal
title: 'A review of survodutide: a new dual acting agonist.'
year: 2026
pmid: '41855048'
authors:
- Yathindra MR
rubino-2026:
id: rubino-2026
type: journal
title: >-
Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in
obesity through clinical trial simulation.
year: 2026
pmid: '41704810'
authors:
- Rubino DM
zimmermann-2026:
id: zimmermann-2026
type: journal
title: >-
Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with
appetite regulation.
year: 2026
pmid: '41638399'
authors:
- Zimmermann T
long-2026:
id: long-2026
type: journal
title: >-
Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of
the dual GCGR/GLP-1R agonist survodutide in mice.
year: 2026
pmid: '41388343'
authors:
- Long F
elmendorf-2026:
id: elmendorf-2026
type: journal
title: 'IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.'
year: 2026
pmid: '41478576'
authors:
- Elmendorf AJ
patil-2026:
id: patil-2026
type: journal
title: >-
Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future
Directions.
year: 2026
pmid: '41831171'
authors:
- Patil R
andonie-2026:
id: andonie-2026
type: journal
title: >-
Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of
Clinical Trials.
year: 2026
pmid: '41466530'
authors:
- Andonie CR
abulehia-2026:
id: abulehia-2026
type: journal
title: >-
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of
Randomised Controlled Trials.
year: 2026
pmid: '41787737'
authors:
- Abulehia A
azam-2026:
id: azam-2026
type: journal
title: >-
Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of
Randomised Controlled Trials.
year: 2026
pmid: '41804840'
authors:
- Azam MH
ji-2026:
id: ji-2026
type: journal
title: >-
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized
controlled trial.
year: 2026
pmid: '41875890'
authors:
- Ji L
abdul-2026:
id: abdul-2026
type: journal
title: >-
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type
2 diabetes.
year: 2026
pmid: '41820018'
authors:
- Abdul Fasi M
gan-2026:
id: gan-2026
type: journal
title: >-
Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum
Stress, Improving Lipid Metabolism and Alleviating Inflammation.
year: 2026
pmid: '41901218'
authors:
- Gan L
li-2025:
id: li-2025
type: journal
title: >-
Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional
Chinese Medicine, and emerging therapies.
year: 2025
pmid: '41488145'
authors:
- Li X
chan-2026:
id: chan-2026
type: journal
title: 'Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.'
year: 2026
pmid: '41711462'
authors:
- Chan ZH
chen-2026:
id: chen-2026
type: journal
title: A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management.
year: 2026
pmid: '41710707'
authors:
- Chen Q
liu-2024:
id: liu-2024
type: journal
title: The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury.
year: 2024
pmid: '38943972'
authors:
- Liu G
sun-2025:
id: sun-2025
type: journal
title: 'Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy.'